Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 10;15(22):5357.
doi: 10.3390/cancers15225357.

Current Data and Future Perspectives on Patients with Atrial Fibrillation and Cancer

Leonardo De Luca  1 , Massimiliano Camilli  2 , Maria Laura Canale  3 , Raffaella Mistrulli  4 , Federico Andreoli  4 , Guido Giacalone  4 , Fabio Maria Turazza  5 , Domenico Gabrielli  1 , Irma Bisceglia  1
Affiliations
Review

Current Data and Future Perspectives on Patients with Atrial Fibrillation and Cancer

Leonardo De Luca et al. Cancers (Basel). .

Abstract

Atrial fibrillation (AF) is an increasingly recognized comorbidity in patients with cancer. Indeed, cancer patients have a significantly higher incidence of AF than that observed in the general population. A reciprocal relationship between these two diseases has been observed, as much as some assume AF to be a marker for occult cancer screening, especially in older adults. The pathophysiological mechanisms are many and varied, including the underlying pro-inflammatory state, specific treatments (chemo- and radiotherapy), and surgery. The therapeutic management of patients with cancer and AF involves the same rhythm and frequency control strategies as the general population; however, the numerous interactions with chemotherapeutics, which lead to a significant increase in side effects, as well as the extreme fragility of the patient, should be considered. Anticoagulant therapy is also a complex challenge to address, as bleeding and stroke risk scores have not been fully assessed in this subpopulation. Furthermore, in large studies establishing the efficacy of direct oral anticoagulants (DOACs), cancer patients have been underrepresented. In this review, we elaborate on the mechanisms linking AF to cancer patients with a particular focus on the therapeutic challenges in this population.

Keywords: anticoagulation; atrial fibrillation; cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pathogenesis of atrial fibrillation associated with cancer. ANS: autonomic nervous system; CV: cardiovascular; * obesity, hypertension, DM, CVDs (HF, VHD, IHD, cardiomyopathies, cardiac amyloidosis). Created with Biorender.com.
Figure 2
Figure 2
Structured approach to anticoagulation for atrial fibrillation in patients with cancer. AF: atrial fibrillation; CHA2DS2-VASc: congestive heart failure, hypertension, age ≥ 75 years (2 points), diabetes mellitus, stroke (2 points), vascular disease, age 65–74 years, sex category (female); eGFR: estimated glomerular filtration rate; GI: gastrointestinal; GU: genitourinary; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs or alcohol. Created with Biorender.com.
See this image and copyright information in PMC

References

    1. Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur. Heart J. 2022;43:4229–4361. doi: 10.1093/eurheartj/ehac244. - DOI - PubMed
    1. Madnick D.L., Fradley M.G. Atrial Fibrillation and Cancer Patients: Mechanisms and Management. Curr. Cardiol. Rep. 2022;24:1517–1527. doi: 10.1007/s11886-022-01769-3. - DOI - PubMed
    1. Aghel N., Baro Vila R.C., Lui M., Hillis C., Leong D.P. Diagnosis and Management of Cardiovascular Effects of Bruton’s Tyrosine Kinase Inhibitors. Curr. Cardiol. Rep. 2023;25:941–958. doi: 10.1007/s11886-023-01916-4. - DOI - PubMed
    1. Boriani G., Menna P., Morgagni R., Minotti G., Vitolo M. Ibrutinib and Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia: Focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death. Chemotherapy. 2022;68:61–72. doi: 10.1159/000528019. - DOI - PubMed
    1. O’Neal W.T., Lakoski S.G., Qureshi W., Judd S.E., Howard G., Howard V.J., Cushman M., Soliman E.Z. Relation between cancer and atrial fibrillation (from the REasons for Geographic and Racial Differences in Stroke Study) Am. J. Cardiol. 2015;115:1090–1094. doi: 10.1016/j.amjcard.2015.01.540. - DOI - PMC - PubMed

LinkOut - more resources